BeiGene, Ltd.
百濟神州有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 06160)

DATE OF FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS ANNOUNCEMENT AND DATE OF AUDIT COMMITTEE MEETING

BeiGene, Ltd. (the "**Company**") hereby announces that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 (after the trading hours of the Hong Kong Stock Exchange). A meeting of the audit committee of the board of directors (the "**Board**") will be held on February 27, 2025 for the purposes of, inter alia, considering and approving the audited financial results of the Company and its subsidiaries for the year ended December 31, 2024 prepared in accordance with U.S. Generally Accepted Accounting Principles ("**U.S. GAAP**") and the applicable rules of the U.S. Securities and Exchange Commission (the "**SEC**") and its publication.

Following the release of the financials, the Company will host a conference call with BeiGene management at 8:00 a.m. U.S. Eastern Time on Thursday, February 27, 2025 (9:00 p.m. Hong Kong Time on Thursday, February 27, 2025).

The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website.

The Company will further issue an announcement of its audited financial results for the year ended December 31, 2024 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HK Listing Rules**") on or before March 31, 2025, which are expected to be the same as the annual results prepared in accordance with U.S. GAAP and the applicable rules of the SEC, except for specific additional information required by the HK Listing Rules, together with a reconciliation of the Company's annual results from U.S. GAAP to International Financial Reporting Standards.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, February 13, 2025

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.